compounding glp-1 news LegitScript's Data Reveals 1200% Increase in Violative and Problematic Advertisements for Medications FDA proposes a new GLP-1

In a development that could reshape diabetes care in Canada, the path has been cleared for generic versions of Ozempic and Wegovy to enter the Canadian market in 2026

While challenges with adherence, side effects, and weight regain upon discontinuation have prompted the search for additional strategies, targets like GLP-1R, GIPR, and GDF8 (Myostatin) still remain the most highly relevant and active areas of research for developing effective obesity treatments

We love it

Learn what evidence shows about colorectal cancer risk.

The widespread prevalence of diabetes, caused by impaired insulin secretion and insulin resistance, is now a worldwide health problem

Omada acts as a GLP1 maximizer, translating the biology of these medications into durable weight health at scale